Search Results - (Author, Cooperation:D. Leroux)
-
1Nils Scharnhorst, Javier Cerrillo, Johannes Kramer, Ian D. Leroux, Jannes B. Wübbena, Alex Retzker, and Piet O. Schmidt
American Physical Society (APS)
Published 2018Staff ViewPublication Date: 2018-08-28Publisher: American Physical Society (APS)Print ISSN: 1050-2947Electronic ISSN: 1094-1622Topics: PhysicsKeywords: Atomic and molecular processes in external fields, including interactions with strong fields and short pulsesPublished by: -
2Liang, K., Carmone, S., Brambilla, D., Leroux, J.-C.
American Association for the Advancement of Science (AAAS)
Published 2018Staff ViewPublication Date: 2018-05-10Publisher: American Association for the Advancement of Science (AAAS)Electronic ISSN: 2375-2548Topics: Natural Sciences in GeneralPublished by: -
3C. Bertolotto ; F. Lesueur ; S. Giuliano ; T. Strub ; M. de Lichy ; K. Bille ; P. Dessen ; B. d'Hayer ; H. Mohamdi ; A. Remenieras ; E. Maubec ; A. de la Fouchardiere ; V. Molinie ; P. Vabres ; S. Dalle ; N. Poulalhon ; T. Martin-Denavit ; L. Thomas ; P. Andry-Benzaquen ; N. Dupin ; F. Boitier ; A. Rossi ; J. L. Perrot ; B. Labeille ; C. Robert ; B. Escudier ; O. Caron ; L. Brugieres ; S. Saule ; B. Gardie ; S. Gad ; S. Richard ; J. Couturier ; B. T. Teh ; P. Ghiorzo ; L. Pastorino ; S. Puig ; C. Badenas ; H. Olsson ; C. Ingvar ; E. Rouleau ; R. Lidereau ; P. Bahadoran ; P. Vielh ; E. Corda ; H. Blanche ; D. Zelenika ; P. Galan ; F. Aubin ; B. Bachollet ; C. Becuwe ; P. Berthet ; Y. J. Bignon ; V. Bonadona ; J. L. Bonafe ; M. N. Bonnet-Dupeyron ; F. Cambazard ; J. Chevrant-Breton ; I. Coupier ; S. Dalac ; L. Demange ; M. d'Incan ; C. Dugast ; L. Faivre ; L. Vincent-Fetita ; M. Gauthier-Villars ; B. Gilbert ; F. Grange ; J. J. Grob ; P. Humbert ; N. Janin ; P. Joly ; D. Kerob ; C. Lasset ; D. Leroux ; J. Levang ; J. M. Limacher ; C. Livideanu ; M. Longy ; A. Lortholary ; D. Stoppa-Lyonnet ; S. Mansard ; L. Mansuy ; K. Marrou ; C. Mateus ; C. Maugard ; N. Meyer ; C. Nogues ; P. Souteyrand ; L. Venat-Bouvet ; H. Zattara ; V. Chaudru ; G. M. Lenoir ; M. Lathrop ; I. Davidson ; M. F. Avril ; F. Demenais ; R. Ballotti ; B. Bressac-de Paillerets
Nature Publishing Group (NPG)
Published 2011Staff ViewPublication Date: 2011-10-21Publisher: Nature Publishing Group (NPG)Print ISSN: 0028-0836Electronic ISSN: 1476-4687Topics: BiologyChemistry and PharmacologyMedicineNatural Sciences in GeneralPhysicsKeywords: Carcinoma, Renal Cell/*genetics ; Cell Movement/genetics ; Gene Frequency ; *Genetic Predisposition to Disease ; *Germ-Line Mutation ; Humans ; Melanoma/*genetics ; Microphthalmia-Associated Transcription Factor/*genetics ; Neoplasm Invasiveness/genetics ; SumoylationPublished by: -
4Staff View
ISSN: 0165-4608Source: Elsevier Journal Backfiles on ScienceDirect 1907 - 2002Topics: MedicineType of Medium: Electronic ResourceURL: -
5Staff View
ISSN: 1436-3259Keywords: Floods ; estimation ; quantiles ; generalized gamma ; generalized moments ; standard errorSource: Springer Online Journal Archives 1860-2000Topics: Architecture, Civil Engineering, SurveyingEnergy, Environment Protection, Nuclear Power EngineeringGeographyGeosciencesNotes: Abstract The generalized gamma (GG) distribution has a density function that can take on many possible forms commonly encountered in hydrologic applications. This fact has led many authors to study the properties of the distribution and to propose various estimation techniques (method of moments, mixed moments, maximum likelihood etc.). We discuss some of the most important properties of this flexible distribution and present a flexible method of parameter estimation, called the “generalized method of moments” (GMM) which combines any three moments of the GG distribution. The main advantage of this general method is that it has many of the previously proposed methods of estimation as special cases. We also give a general formula for the variance of theT-year eventX T obtained by the GMM along with a general formula for the parameter estimates and also for the covariances and correlation coefficients between any pair of such estimates. By applying the GMM and carefully choosing the order of the moments that are used in the estimation one can significantly reduce the variance ofT-year events for the range of return periods that are of interest.Type of Medium: Electronic ResourceURL: -
6Staff View
ISSN: 0165-4608Source: Elsevier Journal Backfiles on ScienceDirect 1907 - 2002Topics: MedicineType of Medium: Electronic ResourceURL: -
7Leroux, D. ; Sotto, J.J. ; Jacob, M.C. ; Couderc, P. ; Monteil, M. ; Jalbert, P.
Amsterdam : ElsevierStaff ViewISSN: 0165-4608Source: Elsevier Journal Backfiles on ScienceDirect 1907 - 2002Topics: MedicineType of Medium: Electronic ResourceURL: -
8Staff View
ISSN: 0165-4608Source: Elsevier Journal Backfiles on ScienceDirect 1907 - 2002Topics: MedicineType of Medium: Electronic ResourceURL: -
9Staff View
ISSN: 0165-4608Source: Elsevier Journal Backfiles on ScienceDirect 1907 - 2002Topics: MedicineType of Medium: Electronic ResourceURL: -
10Gressin, R. ; Legouffe, E. ; Leroux, D. ; Jacob, M. C. ; Swiercz, P. ; Peach, M. ; Capdevilla, V. ; Rossi, J. F. ; Thyss, A. ; Sotto, J. J.
Springer
Published 1997Staff ViewISSN: 1569-8041Keywords: mantle-cell lymphoma ; non-Hodgkin's lymphoma ; VAD regimenSource: Springer Online Journal Archives 1860-2000Topics: MedicineNotes: Abstract Background: MCL is a well-described clinicobiological entity thatpresents the worst prognosis of the small-cell lymphomas. No treatment isknown as the reference treatment. On the basis, first, of clinicobiologicalsimilarities between MCLs and multiple myelomas and, second, of our experienceof chlorambucil in high intermittent dose in MCLs, we have treated MCL withthe VAD regimen both with and without chlorambucil. Patients and methods: Thirty disseminated MCL patients from threeinstitutions, most in relapse (70%), were treated with the classicalVAD regimen: 4 weeks VAD for 12 patients and VAD with 12 mg chlorambucil(d20–d29) for 5 weeks (VAD + C) for 18 patients. Five patients receivedcomplementary high-dose therapy (Alkeran or cyclophosphamide HD with TBI) andperipheral blood stem-cell transplantation. Results: Complete response was achieved in 43% of the patientsin which 84.5% were treated by VAD + C. The median overall survivalfrom the diagnosis was 52 months, and from the first VAD +/− C (OSvad)was 22.5 months, with a 20.5 month (0–75) median follow-up betweendiagnosis and the first VAD +/− C. The OSvad was significantly betterfor patients with fewer than two prognostic factors (ECOG, lymphocytosis,blastic variant, LDH level, and Ki-67 score). Four of five patients treatedwith HDT and PBSCT were alive in CR 12.5 months (7–22) after the firstVAD +/− C regimen. Conclusion: The VAD regimen appears effective in disseminated MCLpatients and even better when associated with chlorambucil. HDT and PBSCTappear promising in younger patients in CR before HDT. A multicenterprospective study is in preparation to confirm these encouraging results.Type of Medium: Electronic ResourceURL: